Chronic use of Renin-Angiotensin-Aldosterone-System blockers and mortality in COVID-19: a multicenter prospective cohort and literature review.
Fiche publication
Date publication
avril 2021
Journal
Fundamental & clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Gault N, Esposito-Farese M, Revest M, Inamo J, Cabie A, Polard É, Hulot JS, Ghosn J, Chirouze C, Deconinck L, Diehl JL, Poissy J, Epaulard O, Lefèvre B, Piroth L, de Montmollin E, Oziol E, Etienne M, Laouenan C, Rossignol P, Costagliola D, Vidal-Petiot E,
Lien Pubmed
Résumé
The role of renin-angiotensin-aldosterone system (RAAS) blockers on the course of coronavirus disease 2019 (COVID-19) is debated. We assessed the association between chronic use of RAAS blockers and mortality among inpatients with COVID-19, and explored reasons for discrepancies in the literature.
Mots clés
COVID-19, RAAS blockers, angiotensin antagonists, hypertension, mortality, propensity score
Référence
Fundam Clin Pharmacol. 2021 Apr 20;: